Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 13 | 2021 | 68 | 3.920 |
Why?
|
| Chromatography, High Pressure Liquid | 11 | 2021 | 44 | 2.640 |
Why?
|
| Spinal Cord Injuries | 5 | 2023 | 23 | 2.210 |
Why?
|
| Riluzole | 6 | 2023 | 6 | 2.060 |
Why?
|
| Neuroprotective Agents | 4 | 2023 | 13 | 1.650 |
Why?
|
| Paclitaxel | 4 | 2020 | 4 | 1.560 |
Why?
|
| Gastric Bypass | 2 | 2019 | 2 | 1.280 |
Why?
|
| Mycophenolic Acid | 3 | 2017 | 3 | 1.240 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 14 | 1.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 19 | 1.090 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 350 | 0.920 |
Why?
|
| Neck Injuries | 1 | 2023 | 1 | 0.880 |
Why?
|
| Cervical Cord | 1 | 2023 | 2 | 0.880 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2023 | 7 | 0.870 |
Why?
|
| Veratrum Alkaloids | 2 | 2019 | 2 | 0.810 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 21 | 0.790 |
Why?
|
| Animals | 18 | 2021 | 1817 | 0.780 |
Why?
|
| Camptothecin | 2 | 2019 | 10 | 0.770 |
Why?
|
| Plasma | 2 | 2017 | 6 | 0.710 |
Why?
|
| Humans | 19 | 2023 | 5485 | 0.680 |
Why?
|
| Chromatography, Liquid | 6 | 2021 | 38 | 0.660 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 4 | 0.660 |
Why?
|
| Neoplasms | 1 | 2021 | 99 | 0.650 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 4 | 0.620 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2018 | 7 | 0.620 |
Why?
|
| Male | 10 | 2023 | 2770 | 0.620 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 9 | 0.610 |
Why?
|
| Bile | 1 | 2018 | 7 | 0.610 |
Why?
|
| Drug Combinations | 1 | 2018 | 25 | 0.610 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 1 | 0.580 |
Why?
|
| Middle Aged | 6 | 2023 | 1100 | 0.570 |
Why?
|
| Obesity | 1 | 2018 | 118 | 0.560 |
Why?
|
| Polymyxin B | 5 | 2015 | 28 | 0.530 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 3 | 0.530 |
Why?
|
| Rats | 5 | 2021 | 251 | 0.500 |
Why?
|
| Arginine Vasopressin | 1 | 2014 | 2 | 0.470 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 16 | 0.460 |
Why?
|
| Prodrugs | 3 | 2019 | 4 | 0.460 |
Why?
|
| Limit of Detection | 3 | 2019 | 27 | 0.420 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 72 | 0.420 |
Why?
|
| Female | 11 | 2019 | 2816 | 0.400 |
Why?
|
| Administration, Oral | 4 | 2021 | 35 | 0.380 |
Why?
|
| Adult | 5 | 2019 | 1687 | 0.360 |
Why?
|
| Polyethylene Glycols | 3 | 2019 | 28 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2021 | 131 | 0.350 |
Why?
|
| Mice | 8 | 2019 | 719 | 0.330 |
Why?
|
| Copper Radioisotopes | 2 | 2019 | 2 | 0.320 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 5 | 0.320 |
Why?
|
| Calibration | 2 | 2018 | 9 | 0.300 |
Why?
|
| Spinal Cord | 2 | 2018 | 12 | 0.300 |
Why?
|
| Biological Availability | 3 | 2021 | 14 | 0.290 |
Why?
|
| Tissue Distribution | 4 | 2019 | 26 | 0.280 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2017 | 7 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 4 | 2015 | 183 | 0.270 |
Why?
|
| Biological Assay | 2 | 2017 | 33 | 0.270 |
Why?
|
| Child | 2 | 2021 | 657 | 0.250 |
Why?
|
| Liposomes | 2 | 2018 | 25 | 0.250 |
Why?
|
| Infant | 2 | 2016 | 87 | 0.240 |
Why?
|
| Infant, Premature | 2 | 2015 | 19 | 0.240 |
Why?
|
| Child, Preschool | 2 | 2016 | 187 | 0.230 |
Why?
|
| Half-Life | 3 | 2021 | 9 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 195 | 0.220 |
Why?
|
| Prospective Studies | 2 | 2023 | 132 | 0.210 |
Why?
|
| Aged | 2 | 2019 | 860 | 0.200 |
Why?
|
| Kenya | 1 | 2021 | 1 | 0.190 |
Why?
|
| Vincristine | 1 | 2021 | 1 | 0.190 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 1 | 0.190 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 9 | 0.180 |
Why?
|
| Calcitriol | 1 | 2020 | 3 | 0.180 |
Why?
|
| Adolescent | 2 | 2016 | 806 | 0.180 |
Why?
|
| Drug Stability | 2 | 2018 | 6 | 0.180 |
Why?
|
| Temperature | 2 | 2018 | 62 | 0.170 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 7 | 0.170 |
Why?
|
| Exosomes | 1 | 2019 | 5 | 0.170 |
Why?
|
| Weight Loss | 1 | 2019 | 8 | 0.170 |
Why?
|
| Cholesterol | 1 | 2019 | 18 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 8 | 0.160 |
Why?
|
| Lipofuscin | 1 | 2019 | 1 | 0.160 |
Why?
|
| Inflammation | 1 | 2019 | 59 | 0.160 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 50 | 0.160 |
Why?
|
| Linear Models | 1 | 2019 | 60 | 0.160 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 7 | 0.160 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2019 | 21 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 1 | 0.160 |
Why?
|
| Rosuvastatin Calcium | 1 | 2018 | 1 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2018 | 2 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2018 | 8 | 0.160 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2018 | 4 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2018 | 5 | 0.160 |
Why?
|
| Light | 1 | 2019 | 43 | 0.160 |
Why?
|
| Simvastatin | 1 | 2018 | 5 | 0.160 |
Why?
|
| Glycerol | 1 | 2018 | 1 | 0.160 |
Why?
|
| Propylene Glycol | 1 | 2018 | 1 | 0.160 |
Why?
|
| Stromal Cells | 1 | 2018 | 6 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 3 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 148 | 0.160 |
Why?
|
| Drug Design | 1 | 2018 | 16 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 23 | 0.150 |
Why?
|
| Lactones | 1 | 2018 | 10 | 0.150 |
Why?
|
| Solvents | 1 | 2018 | 23 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2018 | 16 | 0.150 |
Why?
|
| Metal Nanoparticles | 1 | 2018 | 30 | 0.150 |
Why?
|
| Retinal Degeneration | 1 | 2019 | 38 | 0.150 |
Why?
|
| Copper | 1 | 2018 | 34 | 0.150 |
Why?
|
| Reference Standards | 2 | 2016 | 13 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 5 | 0.150 |
Why?
|
| Serpins | 1 | 2018 | 3 | 0.150 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 5 | 0.150 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 5 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2019 | 74 | 0.150 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2017 | 1 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2015 | 49 | 0.140 |
Why?
|
| Cell Proliferation | 4 | 2019 | 120 | 0.140 |
Why?
|
| Acetates | 1 | 2017 | 7 | 0.140 |
Why?
|
| Eye Proteins | 1 | 2018 | 36 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 2 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 4 | 0.140 |
Why?
|
| Serum Albumin | 1 | 2016 | 1 | 0.140 |
Why?
|
| Anisoles | 1 | 2016 | 1 | 0.130 |
Why?
|
| Solid Phase Extraction | 1 | 2016 | 1 | 0.130 |
Why?
|
| Atmospheric Pressure | 1 | 2016 | 2 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2023 | 34 | 0.130 |
Why?
|
| Glucuronides | 1 | 2016 | 28 | 0.130 |
Why?
|
| Dopamine | 1 | 2015 | 26 | 0.120 |
Why?
|
| Young Adult | 2 | 2016 | 852 | 0.120 |
Why?
|
| Antiemetics | 1 | 2014 | 1 | 0.120 |
Why?
|
| Brain | 1 | 2018 | 286 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 5 | 0.110 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 19 | 0.110 |
Why?
|
| Body Fluids | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2012 | 10 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2012 | 119 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 12 | 0.100 |
Why?
|
| Models, Molecular | 1 | 2012 | 87 | 0.090 |
Why?
|
| Time Factors | 3 | 2021 | 176 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2010 | 6 | 0.090 |
Why?
|
| Mice, Nude | 2 | 2019 | 24 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2023 | 212 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 175 | 0.070 |
Why?
|
| Injections, Intravenous | 2 | 2018 | 6 | 0.070 |
Why?
|
| Pandemics | 1 | 2023 | 82 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 4 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 5 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 53 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2019 | 18 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 131 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 31 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 15 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2019 | 1 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2019 | 4 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 5 | 0.040 |
Why?
|
| Suspensions | 1 | 2019 | 2 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 13 | 0.040 |
Why?
|
| Tight Junction Proteins | 1 | 2019 | 4 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 3 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 78 | 0.040 |
Why?
|
| Particle Size | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 26 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 2018 | 9 | 0.040 |
Why?
|
| Body Weight | 1 | 2019 | 59 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 86 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 32 | 0.040 |
Why?
|
| Apoptosis | 1 | 2019 | 55 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 14 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 14 | 0.040 |
Why?
|
| Micelles | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 22 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2018 | 30 | 0.040 |
Why?
|
| Polymers | 1 | 2018 | 42 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2018 | 225 | 0.030 |
Why?
|
| Polymyxins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Kidney | 1 | 2015 | 53 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 118 | 0.030 |
Why?
|
| Gels | 1 | 2014 | 5 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 11 | 0.030 |
Why?
|
| Serum | 1 | 2013 | 5 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 5 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 15 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2013 | 8 | 0.030 |
Why?
|
| Lung | 1 | 2013 | 42 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 34 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2012 | 12 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 25 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2012 | 19 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 16 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 17 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 20 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 38 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 30 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 54 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 69 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 242 | 0.020 |
Why?
|
| Excipients | 1 | 2010 | 1 | 0.020 |
Why?
|
| Refrigeration | 1 | 2010 | 1 | 0.020 |
Why?
|
| Bordetella bronchiseptica | 1 | 2010 | 1 | 0.020 |
Why?
|
| Pharmaceutical Solutions | 1 | 2010 | 1 | 0.020 |
Why?
|
| Drug Contamination | 1 | 2010 | 2 | 0.020 |
Why?
|
| Drug Storage | 1 | 2010 | 2 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 79 | 0.020 |
Why?
|